[{"id":"67716777-5690-49d3-993c-981578cca089","acronym":"NUTOBREST","url":"https://clinicaltrials.gov/study/NCT06046755","created_at":"2023-09-21T15:11:09.919Z","updated_at":"2024-07-02T16:35:36.338Z","phase":"","brief_title":"Nutritional Intervention-induced Weight Loss During the Oncological Treatment of Obesity-related Breast Cancer","source_id_and_acronym":"NCT06046755 - NUTOBREST","lead_sponsor":"Hospital Clinico Universitario de Santiago","biomarkers":" TNFRSF8 • TNFA • CD163 • IL6R • IL22 • TSLP • IFNL1 • IFNL2 • MMP3","pipe":"","alterations":" ","tags":["TNFRSF8 • TNFA • CD163 • IL6R • IL22 • TSLP • IFNL1 • IFNL2 • MMP3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 10/15/2023","start_date":" 10/15/2023","primary_txt":" Primary completion: 10/03/2024","primary_completion_date":" 10/03/2024","study_txt":" Completion: 12/21/2025","study_completion_date":" 12/21/2025","last_update_posted":"2023-09-21"},{"id":"1d76bd59-1106-4b42-9f95-8ec48f34176c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05366569","created_at":"2022-05-09T11:56:31.025Z","updated_at":"2024-07-02T16:35:42.352Z","phase":"","brief_title":"Bio-CAR-T BS Study","source_id_and_acronym":"NCT05366569","lead_sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","biomarkers":" IL6 • IL2 • IL10 • FAP • IL17A • IL23A • IL22 • GFAP","pipe":"","alterations":" ","tags":["IL6 • IL2 • IL10 • FAP • IL17A • IL23A • IL22 • GFAP"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/26/2022","start_date":" 04/26/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-07-21"},{"id":"3a1a5254-3234-4524-b5ba-287fea6ff089","acronym":"","url":"https://clinicaltrials.gov/study/NCT03823651","created_at":"2021-03-02T16:53:11.206Z","updated_at":"2024-07-02T16:35:58.847Z","phase":"","brief_title":"A Research Program Targeting Pre- and Peri-transplant Optimization Program (R-PPOP)","source_id_and_acronym":"NCT03823651","lead_sponsor":"Duke University","biomarkers":" IL6 • FLT1 • IL2 • IL10 • VEGFC • FGF • IL17A • IL23A • IL17C • IL21 • IL22 • TSLP • VCAM1 • IL16","pipe":"","alterations":" ","tags":["IL6 • FLT1 • IL2 • IL10 • VEGFC • FGF • IL17A • IL23A • IL17C • IL21 • IL22 • TSLP • VCAM1 • IL16"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/27/2019","start_date":" 06/27/2019","primary_txt":" Primary completion: 10/27/2022","primary_completion_date":" 10/27/2022","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2022-12-20"},{"id":"32c24bdb-718c-4a35-a172-afb3477afdce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05535673","created_at":"2022-09-10T11:56:30.321Z","updated_at":"2024-07-02T16:36:04.124Z","phase":"Phase 1","brief_title":"Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma","source_id_and_acronym":"NCT05535673","lead_sponsor":"Zhengzhou University","biomarkers":" BCL2 • BCL6 • IL6 • CXCL8 • IL2 • IL10 • IL17A • IL22 • IL4 • IL5","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • IL6 • CXCL8 • IL2 • IL10 • IL17A • IL22 • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ThisCART19A"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/02/2022","start_date":" 09/02/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2022-09-12"},{"id":"25fe0366-9fcc-46e6-9e6e-7ecaf7006bd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03683147","created_at":"2022-07-25T23:00:13.654Z","updated_at":"2024-07-02T16:36:06.832Z","phase":"","brief_title":"Mindfulness-Based Stress Reduction in Helping Participants With Metastatic Breast Cancer","source_id_and_acronym":"NCT03683147","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IL6 • TNFA • IL2 • CCL20 • IL10 • IL17A • IL23A • IL1RN • IL21 • IL22 • IFNL2 • IL33","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL2 • CCL20 • IL10 • IL17A • IL23A • IL1RN • IL21 • IL22 • IFNL2 • IL33"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 12/13/2017","start_date":" 12/13/2017","primary_txt":" Primary completion: 06/19/2019","primary_completion_date":" 06/19/2019","study_txt":" Completion: 04/06/2020","study_completion_date":" 04/06/2020","last_update_posted":"2022-07-25"},{"id":"af4f17ef-0362-491c-938f-cb8837f5fbeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04093531","created_at":"2021-04-09T15:55:33.775Z","updated_at":"2024-07-02T16:36:07.598Z","phase":"Phase 1","brief_title":"Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome","source_id_and_acronym":"NCT04093531","lead_sponsor":"University of Rochester","biomarkers":" IL6 • TNFA • IL17A • IL22","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL17A • IL22"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 01/15/2020","start_date":" 01/15/2020","primary_txt":" Primary completion: 05/11/2022","primary_completion_date":" 05/11/2022","study_txt":" Completion: 05/11/2022","study_completion_date":" 05/11/2022","last_update_posted":"2022-07-08"},{"id":"56eaeae2-1ec3-449e-8c3a-81f7351b0c9c","acronym":"Cytokim-01","url":"https://clinicaltrials.gov/study/NCT04928365","created_at":"2021-06-16T18:52:48.657Z","updated_at":"2024-07-02T16:36:28.995Z","phase":"Phase 2","brief_title":"Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy","source_id_and_acronym":"NCT04928365 - Cytokim-01","lead_sponsor":"Blokhin's Russian Cancer Research Center","biomarkers":" VEGFA • IFNG • IL6 • CXCL10 • CXCL9 • IL2 • IL10 • CCL2 • IL22","pipe":"","alterations":" ","tags":["VEGFA • IFNG • IL6 • CXCL10 • CXCL9 • IL2 • IL10 • CCL2 • IL22"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/25/2021","start_date":" 03/25/2021","primary_txt":" Primary completion: 05/11/2021","primary_completion_date":" 05/11/2021","study_txt":" Completion: 03/25/2023","study_completion_date":" 03/25/2023","last_update_posted":"2021-06-16"},{"id":"44b23d2a-b087-4118-a03c-973d0274971d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03753399","created_at":"2021-01-18T18:27:13.189Z","updated_at":"2024-07-02T16:36:29.974Z","phase":"","brief_title":"Effect of Acupuncture for QoL in Gastric Cancer Patients Undergoing Adjuvant Chemotherapy: a Pilot Study","source_id_and_acronym":"NCT03753399","lead_sponsor":"Guangzhou University of Traditional Chinese Medicine","biomarkers":" CD8 • IFNG • IL6 • TNFA • CXCL12 • IL2 • IL10 • CCL4 • FGF • IL18 • IL17A • IL23A • IFNA1 • IL1B • IL21 • IL22 • BDNF","pipe":"","alterations":" ","tags":["CD8 • IFNG • IL6 • TNFA • CXCL12 • IL2 • IL10 • CCL4 • FGF • IL18 • IL17A • IL23A • IFNA1 • IL1B • IL21 • IL22 • BDNF"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 01/04/2019","start_date":" 01/04/2019","primary_txt":" Primary completion: 04/27/2020","primary_completion_date":" 04/27/2020","study_txt":" Completion: 04/27/2020","study_completion_date":" 04/27/2020","last_update_posted":"2021-05-20"},{"id":"0be9bf7d-9d02-4af0-bb3f-96dee38d0cfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03570541","created_at":"2021-01-18T17:34:14.170Z","updated_at":"2024-07-02T16:36:35.994Z","phase":"Phase 4","brief_title":"TQL-block for Laparoscopic Hemicolectomy","source_id_and_acronym":"NCT03570541","lead_sponsor":"Zealand University Hospital","biomarkers":" IL6 • TNFA • IL10 • GZMB • IL18 • IL17A • IL15 • IL1B • IL22","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • GZMB • IL18 • IL17A • IL15 • IL1B • IL22"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 06/28/2018","start_date":" 06/28/2018","primary_txt":" Primary completion: 12/05/2020","primary_completion_date":" 12/05/2020","study_txt":" Completion: 01/03/2021","study_completion_date":" 01/03/2021","last_update_posted":"2021-01-15"},{"id":"e3b724b8-dc90-45ae-a840-0335518b66f4","acronym":"FFEJJICRF","url":"https://clinicaltrials.gov/study/NCT04147312","created_at":"2022-06-24T21:54:48.230Z","updated_at":"2024-07-02T16:36:49.607Z","phase":"","brief_title":"Fufang E'Jiao Jiang Intervening Cancer-related Fatigue","source_id_and_acronym":"NCT04147312 - FFEJJICRF","lead_sponsor":"Xiyuan Hospital of China Academy of Chinese Medical Sciences","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL1B • IL22","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL1B • IL22"],"overall_status":"Unknown status","enrollment":" Enrollment 600","initiation":"Initiation: 10/17/2019","start_date":" 10/17/2019","primary_txt":" Primary completion: 05/31/2021","primary_completion_date":" 05/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2020-02-25"},{"id":"fc2794af-4f70-4d2d-a504-fee50aaa137b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03782428","created_at":"2021-01-18T18:42:24.640Z","updated_at":"2024-07-02T16:37:04.494Z","phase":"","brief_title":"An Evaluation of Probiotic in the Clinical Course of Patients With Colorectal Cancer","source_id_and_acronym":"NCT03782428","lead_sponsor":"Dr. Liyana Zaharuddin","biomarkers":" IFNG • IL6 • TNFA • IL10 • IL17A • IL17C • IL22","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • IL17A • IL17C • IL22"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 08/26/2016","start_date":" 08/26/2016","primary_txt":" Primary completion: 11/16/2018","primary_completion_date":" 11/16/2018","study_txt":" Completion: 11/26/2018","study_completion_date":" 11/26/2018","last_update_posted":"2018-12-20"},{"id":"39d94fa9-761b-4f7d-9a9b-52a865613e4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03777930","created_at":"2021-01-18T18:41:15.246Z","updated_at":"2024-07-02T16:37:04.517Z","phase":"Phase 4","brief_title":"The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol","source_id_and_acronym":"NCT03777930","lead_sponsor":"Shenzhen Fifth People's Hospital","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL21 • IL22","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL21 • IL22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e thalidomide • megestrol"],"overall_status":"Unknown status","enrollment":" Enrollment 200","initiation":"Initiation: 12/10/2018","start_date":" 12/10/2018","primary_txt":" Primary completion: 10/10/2020","primary_completion_date":" 10/10/2020","study_txt":" Completion: 06/10/2021","study_completion_date":" 06/10/2021","last_update_posted":"2018-12-19"}]